In recent years, the analysis of single-cell and spatial data has revolutionized biomedical research, making it possible to observe what happens in biological samples with an unprecedented level of detail. Interpreting this data, however, is not easy because different software offer different results which are hard to compare.

Taking this issue as the starting point, a research group from the University of Trento has developed the "Cell Marker Accordion", a bioinformatics tool that makes the identification of cell types in the new generation data clearer and more robust. The results of the research, conducted in collaboration with Yale University (United States), the University of Trondheim (Norway), Policlinico di Milano and the Institute of Biophysics of the National Research Council - CNR, were published in Nature Communications.

Researchers from the Josep Carreras Leukaemia Research Institute and the Aragon Health Research Institute have just presented a new strategy in the fight against T-cell Acute Lymphoblastic Leukaemia. This novel therapy is based on the use of CAR-T cells designed to target two specific markers of this type of leukaemia: the CD1a and CCR9 proteins. Preclinical results of this new therapeutic approach demonstrate both high efficacy and an excellent safety profile, paving the way for clinical development in the short term.

Patients with glioblastoma (GBM)—a type of brain cancer—have a poor prognosis owing to the aggressive nature of GBM disease and limited GBM treatment options. A new study by researchers from Croatia provides critical insights into the transformative role of artificial intelligence (AI) in advancing the diagnosis and treatment of GBM. From accurately distinguishing tumor tissue in GBM to enabling personalized treatment, AI-based tools and models can revolutionize GBM treatment and care.

In a surprising twist on cellular metabolism, scientists have uncovered a noncanonical role of the metabolic enzymePHGDH in shaping immune responses within breast cancer microenvironment.

Bladder cancer often becomes resistant to standard treatments due to its ability to evade apoptosis, the primary form of cell death targeted by conventional therapies. In a recent study, researchers from China developed a nanomedicine that triggers ferroptosis—a different cell death pathway—without needing external activation. Their proposed system not only killed resistant cancer cells but also enhanced the immune system's anti-tumor response, offering a promising dual-action therapy for bladder cancers.

POSTECH and Linyi University develop ‘SLY,’ a Probe That Glows Yellow Only in Tumor Cells.